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The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors
and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral
tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune
destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others
in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The com-
plex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of
checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.In the current era in oncology emphasizing personalized therapy,
immune checkpoint blockade is distinguished by its ‘‘common
denominator’’ approach. Although the vast somatic mutational
diversity found in most human cancers creates challenges for
therapies targeting individual mutations, it exposes a panoply
of new antigens for potential immune recognition. However, cells
of the adaptive and innate immune systems that recognize and
are poised to attack cancer are held in check by molecular
pathways that suppress their activation and effector functions.
The seminal observation that blocking the prototypical immune
checkpoint receptor cytotoxic T lymphocyte antigen 4 (CTLA-4)
could mediate tumor regression in murine models (Leach et al.,
1996) led to the clinical development and approval of anti-
CTLA-4 as a treatment for patients with advanced melanoma
(Hodi et al., 2010). Subsequently, drugs blocking the distinct
checkpoints Programmed Death 1 (PD-1) and its major ligand
PD-L1 have showngreat promise in treatingmanydiverse cancer
types, fueling the intensive examination of a growing cohort of
unique checkpoint molecules as potential therapeutic targets.
This has revealed new treatment options for patients and has
revolutionized our approach to cancer therapy.
Biology of Immune Checkpoints: The Basics
The rapid-fire clinical successes fromblockingCTLA-4 andPD-1,
the first checkpoint receptors to be discovered, have opened
prospects for extending the potential of cancer immunotherapy
by inhibitingmore recently discovered checkpoint ligands and re-
ceptors. It is clear that, despite some commonalities, CTLA-4 and
PD-1 have distinct patterns of expression, signaling pathways,
and mechanisms of action. Although discovered over 20 years
ago, there are still many unanswered questions about their
biology, particularly in the context of cancer.
The CD28/CTLA-4 System of Immune Modulation
The conventional wisdom underlying our vision of how CTLA-4
blockade mediates tumor regression is that it systemically acti-
vates T cells that are encountering antigens. CTLA-4 represents
the paradigm for regulatory feedback inhibition. Its engagement450 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.down-modulates the amplitude of T cell responses, largely by in-
hibiting co-stimulation by CD28, with which it shares the ligands
CD80 (B7.1) and CD86 (B7.2) (Figure 1; Lenschow et al., 1996).
As a ‘‘master T cell co-stimulator,’’ CD28 engagement amplifies
TCR signaling when the T cell receptor (TCR) is also engaged
by cognate peptide-major histocompatibility complex (MHC)
(Schwartz, 1992). However, CTLA-4 has a much higher affinity
for both CD80 and CD86 compared with CD28 (Linsley et al.,
1994), so its expression on activated T cells dampens CD28
co-stimulation by out-competing CD28 binding and, possibly,
also via depletion of CD80 and CD86 via ‘‘trans-endocytosis’’
(Qureshi et al., 2011). Because CD80 and CD86 are expressed
on antigen-presenting cells (APCs; e.g., dendritic cells and
monocytes) but not on non-hematologic tumor cells, CTLA-4’s
suppression of anti-tumor immunity has been viewed to reside
primarily in secondary lymphoid organs where T cell activation
occurs rather than within the tumor microenvironment (TME).
Furthermore, CTLA-4 is predominantly expressed on CD4+
‘‘helper’’ and not CD8+ ‘‘killer’’ T cells. Therefore, heightened
CD8 responses in anti-CTLA-4-treated patients likely occur indi-
rectly through increased activation of CD4+ cells. Of note, a few
studies suggest that CTLA-4 can act as a direct inhibitory recep-
tor of CD8 T cells (Fallarino et al., 1998; Chambers et al., 1998),
although this role in down-modulating anti-tumor CD8 T cell re-
sponses remains to be directly demonstrated.
The specific signaling pathways by which CTLA-4 inhibits
T cell activation are still under investigation, although activation
of the phosphatases SHP2 and PP2A appears to be important
in counteracting both tyrosine and serine/threonine kinase sig-
nals induced by TCR and CD28 (Rudd et al., 2009). CTLA-4
engagement also interferes with the ‘‘TCR stop signal,’’ which
maintains the immunological synapse long enough for extended
or serial interactions between TCR and its peptide-MHC ligand
(Schneider et al., 2006). Naive and resting memory T cells ex-
press CD28, but not CTLA-4, on the cell surface, allowing co-
stimulation to dominate upon antigen recognition. However,
CTLA-4 is rapidly mobilized to the cell surface from intracellular
Figure 1. Complex Interactions between the CTLA-4/CD28 and PD-1
Families of Receptors and Ligands
Shown are the defined interactions between the co-inhibitory (checkpoint)
receptors CTLA-4 and PD-1 and their ligands and related receptors. The two
known ligands for CTLA-4 are CD80 (B7.1) and CD86 (B7.2). CD86 can
‘‘backward-signal’’ into APCswhen engaged by CTLA-4, inducing the immune
inhibitory enzyme IDO. CD80 and CD86 also bind the co-stimulatory receptor
CD28 on T cells. Recently, another B7 family member, inducible costimulator
ligand (ICOS-L), which was discovered as the ligand for the co-stimulatory
receptor ICOS (not shown), has been reported to bind to CD28, leading to co-
stimulation independent of CD80 or CD86. The two defined ligands for PD-1,
PD-L1 (B7-H1) and PD-L2 (B7-DC), bind to additional molecules. PD-L1 binds
CD80 molecules expressed on activated T cells, mediating inhibition. Addi-
tionally, PD-L1 on APCs appears to provide inhibitory signals (backward
signaling) when it is engaged by PD-1. PD-L2 binds another molecule, RGMb,
which is expressed on macrophages and some epithelial cell types and ap-
pears to deliver an inhibitory immune signal through an as yet undefined
mechanism. Although not identified, genetic evidence from PD-1 knockout
T cells and knockout mice suggests the existence of another receptor for PD-
L2 that is co-stimulatory.
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hour after antigen engagement. The central role of CTLA-4
in maintaining immune tolerance is dramatically demonstrated
by the rapidly lethal systemic immune hyperactivation pheno-
type of Ctla-4 knockout mice (Tivol et al., 1995; Waterhouse
et al., 1995). In humans, anti-CTLA-4 treatment induces ex-
pression of activation markers on circulating T cells (Maker
et al., 2005) and a high rate of inflammatory side effects (Phan
et al., 2003). However, because melanoma patients appear to
possess an unusually high proportion of tumor-reactive T cells,
anti-tumor responses balance autoimmune toxicity and provide
a clinical benefit to roughly 20%of patients with this disease (see
below).
PD-1: Similarities to and Differences from CTLA-4
The PD-1 system of immune modulation bears similarities to
CTLA-4 as well as key distinctions (Parry et al., 2005). Similar
to CTLA-4, PD-1 is absent on resting naive and memory T cells
and is expressed upon TCR engagement. However, in contrast
to CTLA-4, PD-1 expression on the surface of activated T cells
requires transcriptional activation and is therefore delayed
(6–12 hr). Also in contrast to CTLA-4, PD-1 contains a conven-
tional immunoreceptor tyrosine inhibitory motif (ITIM) as well as
an immunoreceptor tyrosine switch motif (ITSM). PD-1’s ITIM
and ITSM bind the inhibitory phosphatase SHP-2. PD-1 engage-
ment can also activate the inhibitory phosphatase PP2A. PD-1
engagement directly inhibits TCR-mediated effector functions
and increases T cell migration within tissues, thereby limiting
the time that a T cell has to survey the surface of interacting
cells for the presence of cognate peptide-MHC complexes.Therefore, T cells may ‘‘pass over’’ target cells expressing lower
levels of peptide-MHC complexes (Honda et al., 2014).
In contrast to CTLA-4, PD-1 blockade is viewed to work
predominantly within the TME, where its ligands are commonly
overexpressed by tumor cells as well as infiltrating leukocytes
(Keir et al., 2008). This mechanism is thought to reflect its im-
portant physiologic role in restraining collateral tissue damage
during T cell responses to infection. In addition, tumor-infiltrating
lymphocytes (TILs) commonly express heightened levels of
PD-1 and are thought to be ‘‘exhausted’’ because of chronic
stimulation by tumor antigens, analogous to the exhausted
phenotype seen in murine models of chronic viral infection,
which is partially reversible by PD-1 pathway blockade (Barber
et al., 2006).
Importantly, the phenotypes of murine knockouts of PD-1 and
its two known ligands are very mild, consisting of late-onset
organ-specific inflammation, particularly when crossed to auto-
immune-prone mouse strains (Nishimura et al., 1999, 2001).
This contrasts sharply with the Ctla-4 knockout phenotype and
highlights the importance of the PD-1 pathway in restricting pe-
ripheral tissue inflammation. Furthermore, it is consistent with
clinical observations that autoimmune side effects of anti-PD-1
drugs are generally milder and less frequent than with anti-
CTLA-4.
Despite the conventional wisdom that CTLA-4 acts early in
T cell activation in secondary lymphoid tissues whereas PD-1 in-
hibits execution of effector T cell responses in tissue and tumors,
this distinction is not absolute. Beyond its role in dampening acti-
vation of effector T cells, CTLA-4 plays a major role in driving the
suppressive function of T regulatory (Treg) cells (Wing et al.,
2008; Peggs et al., 2009). Tregs, which broadly inhibit effector
T cell responses, are typically concentrated in tumor tissues
and are thought to locally inhibit anti-tumor immunity. Therefore,
CTLA-4 blockade may affect intratumoral immune responses by
inactivating tumor-infiltrating Treg cells. Recent evidence has
demonstrated anti-tumor effects from CTLA-4 blockade even
when S1P inhibitors block lymphocyte egress from lymph nodes
(Spranger et al., 2014), indicating that this checkpoint exerts at
least some effects directly in the TME as opposed to secondary
lymphoid tissues. Conversely, PD-1 has been shown to play a
role in early fate decisions of T cells recognizing antigens pre-
sented in the lymph node. In particular, PD-1 engagement limits
the initial ‘‘burst size’’ of T cells upon antigen exposure and can
partially convert T cell tolerance induction to effector differentia-
tion (Goldberg et al., 2007).
Complex Receptor-Ligand Interactions in the PD-1
Pathway: Links and Analogies to the CD28/CTLA-4
System
The receptor-ligand interactions of the PD-1 system appear to
be evenmore complex than the CD28/CTLA-4 system (Figure 1).
The two ligands for PD-1 are PD-L1 (B7-H1, CD274) and PD-L2
(B7-DC, CD273), which share 37% sequence homology and
arose via gene duplication (Dong et al., 1999, Latchman et al.,
2001; Tseng et al., 2001). However, their regulation is highly
divergent. PD-L1 is induced on activated hematopoietic cells
and on epithelial cells by the inflammatory cytokine interferon
(IFN)-g, which is produced by some activated T and natural killer
(NK) cells. PD-L2 has much more selective expression on acti-
vated dendritic cells and some macrophages. It is induced to aCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 451
Figure 2. Two General Mechanisms for
Expression of Checkpoint Ligands
in the TME
The examples in this figure use the PD-1 ligand PD-
L1 for illustrative purposes, although the concept
likely applies to multiple checkpoint ligands. Top:
innate immune resistance. In some tumors, consti-
tutive oncogenic signaling, such as through activa-
tion of the AKT pathway or gene amplification, can
upregulate PD-L1 expression on tumor cells inde-
pendently of inflammatory signals in the TME. Bot-
tom: adaptive immune resistance refers to PD-L1
induction in tumors as an adaptation to the sensing
of an immune attack. In adaptive resistance, PD-L1
is not constitutively expressed but, rather, is
induced by inflammatory signals, such as IFN-g
produced by T cells attempting to execute an active
anti-tumor response. Expression of PD-L1 in a non-
uniform distribution associated with lymphocyte
infiltrates suggests adaptive induction in response
to immune reactivity within the TME. Adaptive
resistance can be generated by cytokine-induced
PD-L1 expression on either tumor cells themselves
or on leukocytes (macrophages, myeloid suppres-
sor cells, dendritic cells, or even lymphocytes) in
the TME. Inhibition of tumor-specific T cells by
PD-L1- or PD-L2-expressing leukocytes may in-
volve cross-presentation of tumor antigens so that
PD-1-dependent inhibition is in cis. Adaptive resis-
tance may be a common mechanism for the intra-
tumoral expression of multiple immune checkpoint
molecules.
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emphasizing differences in regulation of expression of PD-L1
and PD-L2.
Beyond their role as ligands for PD-1, PD-L1 and PD–L2
appear to have additional partners, indicating additional layers
of immunemodulation. An unexpected molecular interaction be-
tween PD-L1 and CD80 has been discovered (Butte et al., 2007;
Park et al., 2010) whereby CD80 expressed on activated T cells
(and possibly APCs) can function as a receptor rather than a
ligand, delivering inhibitory signals when engaged by PD-L1.
The relevance of this interaction in tumor immune resistance
has not yet been determined. Recently, PD-L2 has been shown
to bind to repulsive guidance molecule b (RGMb), which itself
binds at least three other molecules in cis (neogenin and BMP
receptors type I and II) (Xiao et al., 2014). This interaction ap-
pears to be inhibitory independent of PD-1, as demonstrated in
a pulmonary tolerance model. Finally, evidence from murine
models suggests that PD-L2 and, possibly, PD-L1 may bind
to a co-stimulatory T cell receptor (Shin et al., 2003, 2005),
an arrangement reminiscent of the CD80/CD86 ligand pair for
the co-stimulatory CD28 and co-inhibitory CTLA-4 receptors.
Understanding the roles of these various interactions in cancer
is highly relevant for the development of immunomodulatory
drugs and the discovery of biomarkers predictive of therapeutic
response.
Mechanisms of PD-1 Ligand Induction: Implications for
Cancer Immunotherapy
A key finding that encouraged the development of drugs block-
ing the PD-1 pathway for cancer immunotherapy was that PD-1
ligands are upregulated in many human cancers (Dong et al.,
2002), whereas PD-1 is highly expressed on tumor-infiltrating
lymphocytes (Ahmadzadeh et al., 2009; Sfanos et al., 2009).452 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.Indeed, PD-L1 appears to be the major ligand expressed in solid
tumors, whereas PD-L2 (together with PD-L1) is highly ex-
pressed in certain subsets of B cell lymphomas (Ansell et al.,
2015). Exploration of this phenomenon as a central process by
which cancers resist elimination by endogenous tumor-specific
T cells revealed two mechanisms for PD-1 ligand upregulation
in cancer, known as intrinsic and adaptive immune resistance
(Figure 2). These mechanisms are not mutually exclusive and
may co-exist in the same TME. Intrinsic resistance refers to the
constitutive expression of PD-L1 by tumor cells because of ge-
netic alterations or activation of certain signaling pathways,
such as the AKT pathway and STAT3, which are commonly acti-
vated in many cancers (Parsa et al., 2007; Marzec et al., 2008).
Although PD-L1 induction by AKT and STAT3 signaling has
been demonstrated in some tumor cell lines, the importance of
this intrinsic pathway in PD-L1 expression by tumors in vivo re-
mains to be determined. Genetic alterations in B cell lymphoma
subtypes can drive expression of either or both PD-L1 and PD-
L2. Primary mediastinal lymphomas commonly display gene fu-
sions between MHC class II transactivator (CIITA) and PD-L1 or
PD-L2, placing PD-1 ligands under the transcriptional control of
the CIITA promoter, which is highly active in B cell lymphomas
(Steidl et al., 2011). A significant subset of Hodgkin’s lymphoma
has amplification of chromosome 9p23-24, where PD-L1 and
PD-L2 reside, resulting in overexpression of both ligands. Other
cancers, such as a subset of Epstein-Barr virus-induced gastric
cancers, also display gene amplification with consequent induc-
tion of PD-L1 and PD-L2.
The second mechanism, adaptive resistance, refers to the
induction of PD-L1 expression on tumor cells in response to spe-
cific cytokines, in particular IFN-g. Because IFN-g is only pro-
duced by activated Th1-type helper CD4 cells, activated CD8
Cancer Cell
Perspectivecells, and NK cells, this mechanism represents an adaptation of
tumor cells upon ‘‘sensing’’ an inflammatory immune microenvi-
ronment that ‘‘threatens’’ the tumor. Indeed, human tumors
show significant correlations between PD-L1 expression, levels
of T cell infiltration, and IFN-g in the TME (Taube et al., 2012;
Spranger et al., 2013). Other inhibitory molecules in the TME,
such as indoleamine 2030 dioxygenase (IDO),which inhibits immu-
nity locally via conversion of tryptophan to kynurenines, are also
induced by IFN-g and coordinately upregulated with PD-L1. The
concept of adaptive resistance does not solely apply to induction
of PD-L1 on tumor cells. Early studies demonstrated that PD-L1
expression on myeloid cells, including dendritic cells, can signifi-
cantly impair activation of tumor-specific T cells. Inhibition of
T cell responses can be mediated by PD-L1+ suppressive
myeloid cells or dendritic cells (DCs) in the TME as well as in tu-
mor-draining lymph nodes (Curiel et al., 2003). In some tumors,
such as microsatellite instability (MSI) colon cancer, myeloid
rather than tumor cells are the major cell type expressing PD-L1
(Llosa et al., 2015). A recent report suggests that PD-L1 expres-
sion by infiltrating myeloid cells rather than tumor cells is more
predictive of response to PD-1 pathway blockade (Herbst et al.,
2014). The relative importanceofPD-L1expressionon leukocytes
in the TME, which would provide ‘‘third-party’’ inhibition, versus
direct expression by the tumor cells, remains to be determined.
Implications of Adaptive Immune Resistance
The adaptive resistance mechanism of intratumoral PD-L1 in-
duction, together with the broad therapeutic activity of PD-1
pathway blockade in human cancer, validates one of the most
important tenets underlying cancer immunology and immuno-
therapy, namely, that many cancer patients contain a significant
repertoire of tumor-specific T cells capable of killing their tumor
save for the adaptive induction of immune checkpoints in the
TME. It also implies that PD-L1 expression in the tumor repre-
sents a measure of the potential for a patient’s immune system
to recognize the tumor. One of the major unanswered questions
is this: what are the dominant antigenic targets that T cells recog-
nize when checkpoints are blocked? Circumstantial evidence
supports the notion that neoantigens created by the multiple
somatic mutations in cancers provide such targets. Indeed, a
recent report has demonstrated that melanomas with higher
mutational loads were more responsive to anti-CTLA-4 therapy
(Snyder et al., 2014). Also, the tumor types that have been shown
to respond to anti-PD-1/PD-L1 therapy tend to be those with
higher median mutational loads (i.e., carcinogen-induced can-
cers such as melanoma, lung, bladder, and head and neck can-
cers). However, there has been much evidence over the past 20
years that shared self-antigens upregulated in tumors by epige-
netic mechanisms (e.g., cancer-testis antigens) are also able
to provide selective tumor targeting. The relative importance
of mutation-dependent, tumor-specific neoantigens versus
tumor-associated self-antigens as T cell targets remains to be
determined.
Finally, the adaptive resistance mechanism has profound im-
plications for developing synergistic combinatorial cancer im-
munotherapies. One of the most promising general approaches
to immunotherapy utilizes positive drivers of anti-tumor immune
responses, such as vaccines, intratumoral injection of immune
activators, and co-stimulatory receptor agonists. These modal-
ities with the potential to enhance anti-tumor responses wouldalso be expected to enhance the adaptive induction of check-
points like PD-1 ligands. This has, in fact, been demonstrated
in animal models of vaccination (Fu et al., 2014). Therefore, pos-
itive drivers of anti-tumor immunity may be synergistic with PD-1
pathway inhibitors. Such approaches are just beginning to enter
the clinic.
Clinical Impact of Drugs Blocking CTLA-4 and PD-1
Anti-CTLA-4
The anti-CTLA-4 monoclonal antibodies (mAbs) ipilimumab, a
fully human IgG1 (Bristol-Myers Squibb), and tremelimumab, a
fully human IgG2 (Pfizer, MedImmune), were the first immune
checkpoint-blocking drugs to enter clinical testing in oncology.
Although designed as CTLA-4-blocking mAbs, these drugs
have recently been postulated to have unique functions en-
dowed by their specific isotypes, with evidence suggesting
that ipilimumab may deplete Tregs overexpressing CTLA-4
(Selby et al., 2013). In 2011, ipilimumab was approved in the
United States and Europe as therapy for advanced unresectable
melanoma based on results from two phase III trials showing
significant extensions in overall survival (OS) (Hodi et al., 2010;
Robert et al., 2011). Long-term follow-up in a pooled meta-anal-
ysis of 1,861 melanoma patients receiving ipilimumab in phase II
or III trials revealed durable survival in approximately 20%, in
some cases extending to 10 years (Schadendorf et al., 2015).
Interestingly, this survival rate is approximately double the
observed rate of tumor regressions measured by standard
oncologic criteria (10% complete responses [CRs] and partial
responses [PRs]). Factors contributing to this phenomenon
may include prolonged disease stabilization, unconventional
‘‘immune-related’’ response patterns, or a heightened respon-
siveness of ipilimumab-refractory patients to subsequent thera-
pies. Although tremelimumab, a distinct CTLA-4-blocking mAb,
showed promise in early-phase melanoma trials, it did not meet
its designated endpoint when randomized against standard
chemotherapy in a first-line phase III melanoma trial (Ribas
et al., 2013).
Ipilimumab has so far shown only modest anti-tumor effects in
non-melanoma cancers, and tremelimumab is still in early testing
for these indications (reviewed in Weber, 2014). Kidney, lung,
and prostate cancer have been the most intensively studied.
In a phase II study of metastatic renal cell carcinoma (RCC,
n = 61), a partial response rate of 10%was observedwith ipilimu-
mab monotherapy (Yang et al., 2007). In lung cancer, treatment-
naive patients with non-small-cell lung cancer (NSCLC) (n = 204)
or extensive disease small-cell lung cancer (ED-SCLC) (n = 130)
received standard chemotherapy alone or combined with ipili-
mumab during initial (‘‘concurrent’’) or later (‘‘phased’’) chemo-
therapy cycles in a phase III trial (Lynch et al., 2012; Reck
et al., 2013). For both diseases, a brief but statistically significant
1-month extension of progression-free survival measured by im-
mune-related criteria (irPFS) was observed in patients receiving
phased ipilimumab plus chemotherapy compared with chemo-
therapy alone. In NSCLC, there was also a significant 1-month
extension of PFS measured by standard criteria in the phased
ipilimumab arm. Although ipilimumab did not have a significant
impact on OS in either NSCLC or ED-SCLC, a subset analysis
appeared to show improved activity in patients with squamous
NSCLC, providing the basis for an ongoing phase III trial ofCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 453
Table 1. Drugs in Clinical Development that Block PD-1 or PD-L1
Target Drug Name Other Names Source
Isotype and
Characteristics Clinical Testing Phase
PD-1 MEDI0680 AMP-514 MedImmune/ AstraZeneca information not available phase I
nivolumab Opdivo, BMS-936558,
MDX-1106, ONO-4538
Bristol-Myers Squibb, Ono
Pharmaceuticals
fully human IgG4a approved, treatment-
refractory unresectable
melanoma (Japan, United
States) and squamous
NSCLC (United States)
pembrolizumab Keytruda, MK-3475,
lambrolizumab
Merck humanized IgG4 approved, treatment-
refractory unresectable
melanoma (United States)
pidilizumab CT-011 CureTech humanized IgG1 phase I-II
PD-L1 BMS-936559 MDX-1105 Bristol-Myers Squibb fully human IgG4a phase I
MEDI4736 none MedImmune/ AstraZeneca Fc-modified human IgG1b phase I-III
MPDL3280A RG7446 Genentech/ Roche Fc-modified human IgG1b phase I-III
MSB0010718C none EMD Serono fully human IgG1a phase I-II
aFully human mAbs were produced in genetically engineered mice.
bFc-modified mAbs were engineered to abrogate ADCC and complement-dependent cytotoxicity (CDC).
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of ipilimumab in metastatic castration-resistant prostate cancer
(mCRPC) have yielded weak but positive signals of activity. In
phase I/II trials in which patients received ipilimumab alone or
combined with systemic granulocyte-macrophage colony-stim-
ulating factor or focal radiotherapy, prostate-specific antigen re-
ductions ofR50%were observed in some patients, and isolated
examples of measurable tumor regression were reported (Fong
et al., 2009; Slovin et al., 2013), supporting further study. In a
phase III trial of ipilimumab versus placebo after bone-directed
radiotherapy in 799 patients with docetaxel-refractory mCRPC,
median OS was 11.2 versus 10.0 months, respectively (p =
0.053), failing to meet the trial’s primary endpoint (Kwon et al.,
2014). However, there was a statistically significant 1-month
improvement in PFS and a suggestion that OS was prolonged
in a subgroup of patients with favorable prognostic features. A
separate phase III trial of ipilimumab in chemotherapy-naive pa-
tients with asymptomatic or minimally symptomatic mCRPC
without visceral metastases has recently completed accrual.
Valuable clinical experience gained from studies of anti-
CTLA-4 mAbs paved a path for accelerated development of
other drugs in class by providing a framework for treatment strat-
egy, toxicity management, and efficacy evaluation. New princi-
ples emerged that distinguished immune checkpoint blockade
from traditional cancer therapies. First, a new category of side
effects, so-called ‘‘immune-related adverse events’’ (irAEs),
was recognized and characterized, leading to algorithm devel-
opment for early detection and management. Drug-related irAEs
were severe in 15%–30% of patients receiving anti-CTLA-4,
sometimes resulting in fatalities. These irAEs were associated
with inflammation in normal tissues such as the gut, skin, and
endocrine glands and resembled phenotypes observed in hu-
man CTLA-4 heterozygotes with reduced CTLA-4 expression
(Topalian and Sharpe, 2014). Their occurrence in individuals
with no prior history of autoimmunity validates the mechanism
of action of anti-CTLA-4 in ‘‘releasing the brakes’’ on immune re-
sponses and underscores the precarious balance that normally454 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.exists between self-tolerance and autoimmunity. Second, a
new category of clinical response termed ‘‘immune-related
response’’ was recognized in which major and durable tumor
regressions could occur after apparent initial disease progres-
sion on treatment (Wolchok et al., 2009). Tumor enlargement
measured by conventional radiologic scans may result from
drug-induced inflammation at tumor sites or could reflect actual
tumor growth followed by delayed regression. Such phenomena
pose challenges for the appropriate management of individual
patients and the selection of informative endpoints for trials of
immune checkpoint-blocking drugs.
Drugs Blocking the PD-1 Pathway
Information garnered from trials of anti-CTLA-4 agents fast-for-
warded the development of drugs blocking PD-1 or its major
ligand, PD-L1. As predicted by murine models, these drugs
have heightened tumor selectivity and reduced toxicity com-
pared with anti-CTLA-4, supporting their administration in an
outpatient setting. Furthermore, although they are effective
against advanced treatment-refractory melanoma, with recent
regulatory approvals for two anti-PD-1 drugs in this setting,
they also appear to have a much broader spectrum of anti-tumor
activity than anti-CTLA-4. Reproducible and durable regressions
of epithelial cancers (lung, head and neck, and bladder cancers,
among others) have catapulted the launching of hundreds of
ongoing clinical trials in diverse disease indications. Although
several different anti-PD-1/PD-L1-blocking mAbs are currently
in clinical testing (Table 1), the fact that anti-tumor activity has
been observed with all of them highlights the PD-1 pathway as
a dominant intratumoral immunosuppressive pathway and a
key target in cancer therapy.
The first-in-human trial of nivolumab anti-PD-1 provided sem-
inal evidence that this treatment approach could potentially
impact diverse cancer types, including common epithelial can-
cers, with objective responses reported in patients with mela-
noma, kidney, and colorectal cancer (Brahmer et al., 2010).
A transient tumor regression in one patient with NSCLC
provided the impetus for investigating a larger NSCLC cohort
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types (Topalian et al., 2012). Results from this trial showed
notable objective response rates in patients with advanced treat-
ment-refractory NSCLC (17%, n = 129), RCC (27%, n = 34), and
melanoma (31%, n = 107). Importantly, responseswere quite du-
rable, with many persisting even after drug discontinuation, and
long-term follow-up revealed OS of 9.9, 22.4, and 16.8 months,
respectively (Topalian et al., 2014). These non-randomized data
compared favorably to historical response rates in similar patient
populations, spurring phase III testing of nivolumab in all three
cancers. A recent phase III report showed the superiority of
first-line nivolumab versus standard chemotherapy in patients
with advanced melanoma (Robert et al., 2015). These findings
have incentivized the aggressive clinical development of PD-1
pathway-blocking drugs by multiple pharmaceutical and bio-
technology companies (Table 1), and the clinical activity of these
drugs in melanoma, RCC, and NSCLC has been confirmed
(Brahmer et al., 2012; Hamid et al., 2013; Herbst et al., 2014;
Motzer et al., 2014). Nivolumab was recently approved by the
Food and Drug Administration for chemotherapy-refractory
squamous NSCLC. However, the full activity spectrum of PD-1
pathway-blocking drugs is not yet known, with recent evidence
of efficacy in advanced chemotherapy-refractory bladder cancer
(Powles et al., 2014), Hodgkin’s lymphoma (Ansell et al.,
2015), head and neck, gastric, triple-negative breast, and
ovarian cancers.
Combination Therapies Based on PD-1 Pathway
Blockade
Despite these promising results, the majority of patients treated
with anti-PD-1/PD-L1 monotherapies do not achieve objective
responses, and most tumor regressions are partial rather than
complete. Animal models suggest that treatment combina-
tions based on PD-1 pathway blockade may be synergistic,
including anti-CTLA-4 or other checkpoint inhibitors, chemo-
therapy, tyrosine kinase inhibitors, focal irradiation, cancer vac-
cines, or immune agonist mAbs. Appropriate preclinical models
are valuable in providing a basis for prioritizing clinical transla-
tion. A wide variety of treatment combinations are now under
clinical development in diverse cancer types. Early and
substantial tumor regressions observed with a combination
of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) in
advanced melanoma have garnered attention, although associ-
ated irAEs were also amplified (Wolchok et al., 2013). Results
from ongoing prospectively randomized trials will be needed
to define the role of this treatment combination in melanoma
and other cancers.
Biomarkers of Response
As mentioned earlier, studies of peripheral blood have yielded
pharmacodynamic evidence of global T cell activation in patients
receiving anti-CTLA-4 (Maker et al., 2006), although these
changes do not appear to correlate with clinical outcomes. Pe-
ripheral T cell activation does not occur to the same degree in
patients receiving anti-PD-1/PD-L1 (Brahmer et al., 2010), as
might be anticipated because the TME is thought to be the
main site of activity of this pathway. Accordingly, tumor tissue
has become the focal point for exploring potential biomarkers
of response to anti-PD-1 drugs. Early studies revealed a correla-
tion between pretreatment tumor cell expression of the ligand
PD-L1 by immunohistochemistry (IHC) and the likelihood ofresponse to anti-PD-1 (Brahmer et al., 2010; Topalian et al.,
2012). With the advent of several new automated PD-L1 IHC
tests and interrogation of hundreds of patients with a variety of
cancer types, a significant but not absolute relationship between
PD-L1 expression in the TME and responsiveness to PD-1
pathway blockade has been confirmed. The potential impor-
tance of PD-L1 expression by infiltrating immune cells (Herbst
et al., 2014), the presence and location of CD8+ tumor-infiltrating
lymphocytes (Tumeh et al., 2014), and other factors (Taube et al.,
2014) are currently under intense study individually and in com-
bination to discern more sensitive and specific predictors of clin-
ical outcomes.
On the Horizon: Targeting Novel Checkpoints
Although antibody blockers of CTLA-4 and PD-1 are the focus of
clinical attention at this time, it is likely that blockade of additional
checkpoints will result in even further clinical activity. This is
because multiple checkpoints appear to be co-expressed with
PD-L1 and PD-1 in tumors. We review here some of the most
actively studied ‘‘next-generation’’ checkpoint molecules for
which antibody blockers are already in the clinic or soon to be
tested in clinical trials, many in combination with anti-PD-1 or
anti-PD-L1.
Lymphocyte Activation Gene 3
Lymphocyte activation gene 3 (LAG-3, CD223) is an immune
checkpoint molecule expressed on activated T cells (Huard
et al., 1994), NK cells (Triebel et al., 1990), B cells (Kisielow
et al., 2005), and plasmacytoid dendritic cells (Workman et al.,
2009). Structurally, LAG-3 is highly homologous to the CD4
T cell co-receptor and lies proximal to the CD4 gene on human
chromosome 12, but, at the amino acid level, it is less than
20% homologous to CD4, indicating that the two genes likely
diverged early in evolution (Dijkstra et al., 2006). The only known
ligand for LAG-3 is MHC II (Huard et al., 1997), although its struc-
tural interactions with MHC II are more limited than those of CD4
(Fleury et al., 1991; Moebius et al., 1993). Early studies showed
that LAG-3 was selectively upregulated on CD4+ Tregs (Huang
et al., 2004). Here a LAG-3-blocking antibody mitigated Treg ac-
tivity in vivo, and transfection of antigen-specific CD4 T cells with
full length, but not truncated, LAG-3 could confer in vitro Treg
function. More recent studies have also suggest that LAG-3
blockade (or genetic knockout) affects the ability of conventional
T cells (Tconv) to be suppressed by Tregs (Sega et al., 2014;
Durhamet al., 2014). Additionally, LAG-3 has aCD8T cell-intrinsic
role because LAG-3 blocking antibodies were found to augment
CD8 T cell function in vivo in the absence of CD4 T cells Grosso
et al., 2007). As described above, exhausted or dysfunctional
T cells can express multiple immune checkpoint molecules, and
LAG-3 and PD-1 are commonly co-expressed in models of
chronic infection Blackburn et al., 2009) as well as models of
self-antigen recognition (Grosso et al., 2009). These studies
have been extended to human tumors in that a significant fraction
of antigen-specific CD8 T cells in patients with ovarian cancer and
melanoma co-express LAG-3 and PD-1 (Matsuzaki et al., 2010;
Baitsch et al., 2012). Evidence for synergistic immunosuppression
mediated by LAG-3 and PD-1 comes from studies in which dou-
ble-knockout mice were generated. Although neither LAG-3 nor
PD-1 single knockout animals succumb to autoimmunity, com-
bined knockout results in multi-organ lymphocytic infiltration,Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 455
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obtained in models of autoimmunity (Okazaki et al., 2011), rein-
forcing the notion that LAG-3 and PD-1 are potentially synergistic
in regulating T cell function. A role for dual blockade of LAG-3 and
PD-1 in tumor immunity is suggested by studies in which most
tumors implanted in PD-1/LAG-3 double-knockout mice were
rejected, whereas PD-1 single-knockout mice showed delayed
tumor growth. Similarly, combined antibody-mediated blockade
of LAG-3 and PD-1 resulted in tumor rejection in several models
without any short-term evidence of autoimmune side effects. An
anti-LAG-3 blocking mAb has recently entered clinical testing in
cancer (clinical trial NCT01968109) in a phase I trial that includes
cohorts receiving anti-LAG-3 monotherapy or combination ther-
apy with anti-PD-1.
Killer Inhibitory Receptors
NK cells are a population of innate immune cells with well docu-
mented roles in infectious and tumor immunity (Marcus et al.,
2014). Like activated CD8 T cells, NK cells mediate target cell
apoptosis via secretion of preformed granules containing per-
forin and granzymes. However, unlike CD8 T cells, NK cells do
not recognize unique peptides in the context of classical MHC
I molecules. Instead, NK function is controlled by the complex
interplay of a series of activating receptors and killer inhibitory re-
ceptors (KIRs) and their ligands. In humans, KIR molecules are
polymorphic and bind to certain MHC I alleles, and not all KIR/
ligand pairs are equally capable of inhibiting NK cell function.
Indeed, bone marrow transplants in which donor NK cells lack
the ability to be inhibited by host KIR ligands have been shown
to result in lower relapse rates and improved OS, supporting
the importance of this cell type in cancer immunity (Benson
and Caligiuri, 2014). The relative importance of NK cells inmurine
models of cancer immunotherapy has been documented bymul-
tiple studies but is especially highlighted by studies in which NK
cell activation via IL-15 can eradicate fairly advanced tumors in
the absence of CD8 T cells (Liu et al., 2012). So, in a sense,
KIRs can be thought of as immune checkpoint molecules, and
blocking KIRs on NK cells could be exploited to augment anti-tu-
mor immunity. To that end, a fully human anti-KIR mAb has
entered clinical testing. This antibody (initially IPH-2101, Innate
Pharma; now lirilumab, Bristol-Myers Squibb) binds to the hu-
man KIR molecules KIR2DL-1, KIR2DL-2, and KIR2DL-3 as
well as to KIR2DS-1 and KIR2DA-2, preventing their binding to
HLA-C MHC I molecules (Romagne´ et al., 2009). A phase I trial
of anti-KIR in acute myelogenous leukemia has been completed.
Several studies in hematologic and solid cancers are ongoing,
but of particular interest are trials in which lirilumab is being com-
bined with anti-PD-1 (nivolumab, clinical trial NCT01714739) or
with anti-CTLA-4 (ipilimumab, clinical trial NCT01750580). These
trials are important in that each seeks to combine innate immune
activation via anti-KIR with activation of the adaptive immune
system, therefore offering the potential for additive or synergistic
anti-tumor efficacy.
B7-H3
B7-H3 (CD276) was initially identified using a bioinformatics
approach in which human genome databases were queried for
sequences with homology to previously identified B7 family
members (Chapoval et al., 2001). It is a type I transmembrane
protein with single variable and constant immunoglobulin do-
mains. B7-H3 mRNA is widely expressed in normal tissues456 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.(Sun et al., 2002), but protein expression is more restricted and
is controlled by post-transcriptional mechanisms. The under-
standing of B7-H3 biology is complicated by the fact that it
can be expressed on both immune and non-immune cells. On
immune cells, B7-H3 appears to exert a stimulatory role: down-
regulation of B7-H3 expression using anti-sense oligonucleo-
tides inhibits T cell production of IFN-g (Chapoval et al., 2001).
Therefore, B7-H3might be considered not as a classical immune
checkpoint molecule but, rather, as a co-stimulatory receptor
more analogous to CD28. Although this model is supported by
numerous studies (Yi and Chen, 2009), several studies suggest
an alternative model in which B7-H3 down-modulates T cell acti-
vation. These studies include the finding that B7-H3-blocking
antibodies exacerbate disease in the experimental autoimmune
encephalomyelitis (EAE) murine model as well as in several other
models (Suh et al., 2003). In terms of cancer immunity, there is a
similar lack of clarity in that the induction of expression of B7-H3
in tumor cell lines increases their immunogenicity and leads to
more rapid rejection (Luo et al., 2004). But in many human tu-
mors, expression of B7-H3 in situ has been associated with a
poor outcome. This is especially notable in RCC and prostate
cancer, where expression correlates with an increased risk of
death (Crispen et al., 2008; Chavin et al., 2009). Based on the
notion that B7-H3 protein is overexpressed in multiple tumor
types, a mAb with enhanced antibody-dependent cellular cyto-
toxicity (ADCC) function has been developed (Loo et al., 2012)
and has entered clinical trials (clinical trial NCT01391143). This
agent is not being deployed as an immune checkpoint-blocking
antibody. Rather, it is being tested as a traditional tumor-target-
ing antibody similar in concept to rituximab or trastuzumab.
T Cell Immunoglobulin and Mucin-3
T cell immunoglobulin and mucin-3 (TIM-3) is an immune
checkpoint molecule expressed on activated human T cells,
NK cells, and monocytes. TIM-3 knockout mice, similar to
LAG-3 knockouts, do not develop overt autoimmunity (Sa´n-
chez-Fueyo et al., 2003), suggesting that TIM-3 and LAG-3
may have similarly subtle effects in modulating immune cell
function. Consistent with this hypothesis, TIM-3 blockade
accelerates the disease phenotype in murine models prone to
developing autoimmunity, including non-obese diabetic (NOD)
(Sa´nchez-Fueyo et al., 2003) and EAE models (Monney et al.,
2002). Functionally, TIM-3 binds to galectin-9 (as well as several
other ligands), as supported by data showing that administration
of galectin-9 in vitro causes cell death of Th1 cells in a TIM-3-
dependent manner (Zhu et al., 2005). Recent studies showed
that TIM-3 is co-expressed with and binds to CECAM1 and
that this interaction is important in TIM-30s regulatory function
(Huang et al., 2015). In other work, the role of the TIM-3 immune
checkpoint was studied in several murine cancer models (Sa-
kuishi et al., 2010), including the CT26 colon carcinoma, 4T1
mammary carcinoma, and B16 melanoma. Interestingly, TIM-3
was nearly universally co-expressed with PD-1 on the majority
of TILs. Co-expression of both checkpoint molecules reflected
a more exhausted phenotype, functionally defined by a T cell’s
reduced ability to proliferate and secrete IFN-g, IL-2, and tumor
necrosis factor a (TNF-a). Combined blockade was more effec-
tive in controlling tumor growth than blocking either checkpoint
alone, confirming the notion that combined immune checkpoint
blockade offers a potential treatment strategy for a wide variety
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points might synergize with PD-1 to down-modulate T cell
responses to tumors. Anti-human TIM-3 blocking antibodies
have not yet entered the clinic but are under development.
V-Domain Ig-Containing Suppressor of T Cell Activation
V-domain Ig-containing suppressor of T cell activation (VISTA) is
a relatively recently described negative regulator of T cell func-
tion (Wang et al., 2011). Unlike PD-1 and CTLA-4, VISTA is pre-
dominantly expressed on myeloid and granulocytic cells, with
only weak T cell expression in mice and humans (Lines et al.,
2014; Wang et al., 2011). Functionally, VISTA blockade attenu-
ates tumor outgrowth, especially when combined with a
cancer vaccine (Wang et al., 2011). In terms of human cancers,
VISTA expression has been described in colorectal tumors;
here expression appears to be confined to CD11b+ cells,
whereas expression on CD8 T cells was not detected (Lines
et al., 2014). These early studies are relatively limited in scope,
and a more comprehensive analysis of VISTA expression in
various human tumor types is warranted. In addition, the relative
efficacy of VISTA blockade compared with PD-1 or CTLA-4
blockade awaits the development of suitable reagents, but, as
is the case for the other checkpoint molecules discussed above,
the notion that VISTA expression so far appears to be selective
for the myeloid compartment of tumors suggests the possibility
of clinical effects distinct from those mediated by currently
available checkpoint blocking antibodies as well as the potential
for additive or synergistic benefits.
T Cell ITIM Domain: TIGIT
LikeB7-H3, TIGITwas initially identified throughagenomic search
for structures shared among regulatory receptors, including a
conserved ITIM motif (Yu et al., 2009). Initial studies suggested
that TIGIT functions by transmitting a negative signal to DCs,
decreasing IL-12 secretion while simultaneously enhancing IL-
10 levels. A more recent study, however, shows that TIGIT func-
tions as an immune checkpoint, downregulating proliferation of
both murine and human T cells (Johnston et al., 2014). The ligand
for TIGIT is the poliovirus receptor (PVR), but PVRalso binds to the
T cell surface molecule CD226. In this way, TIGIT biology is
perhaps reminiscent of the interaction between B7 molecules
andCTLA-4/CD28. Binding of PVR to TIGITmediates an inhibitory
signal, whereas binding of PVR to CD226 transmits a positive co-
stimulatory signal to T cells. Blocking TIGIT with a specific mAb
showed efficacy in both viral and tumor models, including an ad-
ditive anti-tumor effect when both PD-L1 and TIGIT were blocked
simultaneously. The relevance of these data to human cancer
awaits future clinical development, but it is worth noting that
genomic profiling studies showed that CD8a expression corre-
lates closely with TIGIT expression in tissue from lung cancer
patients (Johnston et al., 2014).
IDO
Although not an immune checkpoint in the classical sense,
several inhibitory pathways mediated by overexpression of IDO
in various tumor types play an important role in downregulating
anti-tumor immunity (Prendergast et al., 2014). As briefly men-
tioned above, IDO catabolizes the breakdown of tryptophan
to kynurenine (and other metabolites). T cells require adequate
tryptophan levels for survival and effector function, and, there-
fore, IDO-mediated tryptophan deficiency results in T cell toler-
ance and lack of effector function and promotes the differentia-tion of naive CD4 T cells into Tregs (Fallarino et al., 2006). In
addition, IDO expression in a relatively small population of
tumor-associated DC allows the suppression of effector T cell
responses (Mellor andMunn, 2004). Both the IDO pathway inhib-
itor D-1MT and small-molecule enzymatic inhibitors of IDO1
(INCB024360 and NLG919) have entered clinical trials, and
phase I data from a trial combining D-1MT (indoximod) with
chemotherapy were published recently, demonstrating tolera-
bility for the combination as well as evidence of anti-tumor activ-
ity (Soliman et al., 2014).
Conclusions
Recent years have seen a rapid expansion of our knowledge of
immune regulation. Basic principles established in laboratory
models of infection, autoimmunity, and transplantation have
proved to be transportable to human cancer, supporting the
development of drugsmodulating anti-tumor immunity. The suc-
cessful application of the immune checkpoint blockers anti-
CTLA-4 in melanoma and anti-PD-1/PD-L1 in multiple cancer
types has established immunotherapy as a viable treatment op-
tion for patients with advanced cancers and has opened the
doors to developing a new generation of immune modulators
that may be most effective when employed in treatment combi-
nations. Armed with a new understanding and unprecedented
opportunities, the field of immunotherapy is now standing on
the threshold of great advances in the war against cancer.
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